⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28432597 | 0.71 | MKNK1 (0.49) | — | |
| SCHEMBL130843 | 0.71 | — | — | |
| SCHEMBL10676088 | 0.69 | — | — | |
| SCHEMBL21414017 | 0.69 | — | — | |
| SCHEMBL14780447 | 0.69 | — | — | |
| SCHEMBL671347 | 0.69 | — | — | |
| SCHEMBL2611107 | 0.69 | — | — | |
| SCHEMBL360179 | 0.69 | — | — | |
| SCHEMBL8081642 | 0.69 | — | — | |
| SCHEMBL4497202 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085061-A1 | PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS | SITRYX THERAPEUTICS LIMITED (GB) | 2026-03-26 | — | — | US | disclosed |
| US-12448367-B2 | Phthalazine derivatives as pyruvate kinase modulators | SITRYX THERAPEUTICS LIMITED (GB) | 2025-10-21 | — | — | US | disclosed |
| EP-4612132-A1 | PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS | Sitryx Therapeutics Limited (GB) | 2025-09-10 | — | — | EP | disclosed |
| EP-4587439-A1 | SULFONE-SUBSTITUTED PYRIDO[3,4-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | Bayer Aktiengesellschaft (DE) | 2025-07-23 | — | — | EP | disclosed |
| US-20250230143-A1 | PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS | SITRYX THERAPEUTICS LIMITED (GB) | 2025-07-17 | — | — | US | disclosed |
| CN-120166987-A | Phthalazine derivatives as pyruvate kinase modulators | 西特瑞治疗有限公司 | 2025-06-17 | — | — | CN | disclosed |
| CN-119894893-A | Sulfone substituted pyrido [3,4-D ] pyrimidine derivatives for the treatment of cancer | 拜耳公司 | 2025-04-25 | — | — | CN | disclosed |
| WO-2024095012-A1 | PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS | SITRYX THERAPEUTICS LIMITED (GB) | 2024-05-10 | — | — | WO | disclosed |
| WO-2024056782-A1 | SULFONE-SUBSTITUTED PYRIDO[3,4-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2024-03-21 | — | — | WO | disclosed |
| US-20230365592-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. | 2023-11-16 | — | — | US | disclosed |
| EP-3551622-B1 | MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR | VERTEX PHARMA (US) | 2020-10-07 | — | — | EP | disclosed |
| CN-111132964-A | Glucocorticoid receptor modulators | 欧瑞克制药公司 | 2020-05-08 | — | — | CN | disclosed |
| US-10577368-B2 | A3 adenosine receptor agonists | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-03-03 | — | — | US | disclosed |
| EP-3609872-A1 | GLUCOCORTICOID RECEPTOR MODULATORS | Oric Pharmaceuticals, Inc. (US) | 2020-02-19 | — | — | EP | disclosed |
| WO-2018191283-A1 | GLUCOCORTICOID RECEPTOR MODULATORS | ORIC PHARMACEUTICALS, INC. (US) | 2018-10-18 | — | — | WO | disclosed |
| WO-2018132372-A1 | SMALL MOLECULE ACTIVATORS OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2018-07-19 | — | — | WO | disclosed |
| WO-2018071343-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2018-04-19 | — | — | WO | disclosed |
| EP-2334637-A1 | NOVEL POTASSIUM CHANNEL BLOCKERS | Xention Limited (GB) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010023446-A1 | NOVEL POTASSIUM CHANNEL BLOCKERS | XENTION LIMITED (GB) | 2010-03-04 | — | — | WO | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |